For most patients, the durability of virologic response was maintained with minimal adjustments to the OBR. Altogether, these data demonstrate the contribution of IBA towards durable viral suppression in TE HIV patients with limited therapeutic options.
Subgroup analyses of TMB-301/311 data show significant efficacy of IBA among patients with one or two other fully active agents, with durable responses regardless of the number of active agents. Patients who combined IBA with DTG showed impressive rates of suppression. Data support the long-term efficacy of IBA-based regimens that include two or three fully
COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH ONE OR TWO FULLY ACTIVE AGENTS Read More »
Ibalizumab is the first long-acting antiretroviral and monoclonal antibody approved for the treatment of HIV-1 infection. With no expected DDIs or cross-resistance with other ARVs, it became a key option for this patient.
In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-week study. Evidence of the emergence of diminished ibalizumab susceptibility was observed in vitro in patients who had virologic failure.
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 Read More »
CLINICAL RESEARCH UPDATE by Jeffrey T. Kirchner, DO, AAHIVS, AAHIVM Chief Medical Officer January 28, 2020
CLINICAL RESEARCH UPDATE by Jeffrey T. Kirchner, DO, AAHIVS, AAHIVM Chief Medical Officer April 7, 2020
CLINICAL RESEARCH UPDATE by Jeffrey T. Kirchner, DO, AAHIVS, AAHIVM Chief Medical Officer March 24, 2020
CLINICAL RESEARCH UPDATE by Jeffrey T. Kirchner, DO, AAHIVS, AAHIVM Chief Medical Officer April 21, 2020
CLINICAL RESEARCH UPDATE by Carolyn Chu, MD, MSc, AAHIVS, AAHIVM Chief Medical Officer March 29, 2022
CLINICAL RESEARCH UPDATE by Carolyn Chu, MD, MSc, AAHIVS, AAHIVM Chief Medical Officer August 16, 2022
